MedTrace Logo

A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis

NCT00529581 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2008-05-28

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and efficacy of C105 in treating the cognitive deficits that can occur due to multiple sclerosis.

Conditions

Interventions

DRUG

C105

Sponsors & Collaborators

  • Cognition Pharmaceuticals, LLC

    lead INDUSTRY

Principal Investigators

  • Frederick Munschauer, MD · SUNY Buffalo

  • Ralph Benedict, PhD · SUNY Buffalo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2008-03-31
Completion
2008-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00529581 on ClinicalTrials.gov